[Combined intravitreal therapy for age-related macular disease].

Abstract

Since the introduction of anti-VEGF drugs for the treatmet of CNV in age-related macular degeneration (AMD), visual acuity can be stabilised or improved in a significant number of patients. There is an ongoing debate on the safety, efficiency and economic aspects related to current intravitreal therapeutic concepts. Twenty-four to 36 hours after 80 % low-fluence verteporfin photodynamic therapy (PDT) a combined phrarmacosurgical intravitreal therapy for 52 patients with wet AMD was conducted (multiple therapy). By performing a 23-gauge core vitrectomy with the Intrector, an intravitreal substitution with BSS, dexamethasone and bevacizumab was achieved via a self-adapting two-channel cannula for aspiration and injection in one probe tip. After 14 months the mean gain in visual acuity (VA) was 0.18 Snellen lines, with VA stabilisation in 14 / 52 (27 %) and VA gain in 38 / 52 (73 %) of the patients. This safe pharmacosurgical regimen indicated a low intravitreal retreatment rate of (13 / 52) 25 %.

• Authors: F Koch, S Scholtz, P Singh, M J Koss
• Journal: Klinische Monatsblatter fur Augenheilkunde (Klin Monbl Augenheilkd) Vol. 225 Issue 12 Pg. 1003-8 (Dec 2008) ISSN: 1439-3999 [Electronic] Germany
• Vernacular Title: Kombinierte intravitreale Therapie zur Behandlung der altersbedingten Makuladegeneration.
• PMID: 19085777 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Steroids
• Vascular Endothelial Growth Factor A

Topics

• Antibodies, Monoclonal (administration & dosage)
• Combined Modality Therapy
• Humans
• Macular Degeneration (therapy)
• Photochemotherapy (trends)
• Steroids (administration & dosage)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)